

10/ 667,111

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and
February 2005
NEWS 17 JAN 26 CA/CAPLUS - Expanded patent coverage to include the Russian
Agency for Patents and Trademarks (ROSPATENT)

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

10/ 667,111

FILE 'HOME' ENTERED AT 15:35:47 ON 08 FEB 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:36:18 ON 08 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

DICTIONARY FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.



Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\STNEXP4\QUERIES\10667111.str



chain nodes :

17 19 20 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

6-23 9-17 19-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 7-14 8-9 9-10 11-12 12-13 13-14

exact/norm bonds :

4-7 5-10 6-23 7-8 8-9 9-10 9-17 19-20

exact bonds :

7-11 7-14 11-12 12-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

10/ 667,111

containing 1 :

G1:X,Ak

Hydrogen count :

8:= exact 1 10:= exact 1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 17:CLASS 19:CLASS 20:CLASS 21:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 X,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sample

SAMPLE SEARCH INITIATED 15:37:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 22 TO 418

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 15:37:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 217 TO ITERATE

10/ 667,111


100.0% PROCESSED 217 ITERATIONS
SEARCH TIME: 00.00.01

50 ANSWERS

L3 50 SEA SSS FUL L1

=> d scan

L3 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Furancarboxylic acid, 5-[[(8'-chloro-2',3'-dihydro-2'-
oxospiro[cyclohexane-1,4' (1'H)-quinazolin]-5'-yl)oxy]methyl]-, ethyl ester
(9CI)
MF C21 H23 Cl N2 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.76

161.97

FILE 'CAPLUS' ENTERED AT 15:37:41 ON 08 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 7 Feb 2005 (20050207/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 5 L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:689239 CAPLUS

DOCUMENT NUMBER: 141:332154

TITLE: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: optimization of 5,8-disubstituted derivatives

AUTHOR(S): Bernardelli, Patrick; Lorthiois, Edwige; Vergne, Fabrice; Oliveira, Chrystelle; Mafroud, Abdel-Kader; Proust, Emmanuelle; Pham, Nga; Ducrot, Pierre; Moreau, François; Idrissi, Moulay; Tertre, Anita; Bertin, Bernadette; Coupe, Magali; Chevalier, Eric; Descours, Arnaud; Berlioz-Seux, Francoise; Berna, Patrick; Li, Mei

CORPORATE SOURCE: Pfizer Global Research and Development, Fresnes, 94265, Fr.


SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(18), 4627-4631
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The optimization of 5,8-disubstituted spirocyclohexane-quinazolinones into potent, selective, soluble PDE7 inhibitors with acceptable in vivo pharmacokinetic parameters is presented. It was also reported that 5'-carboxymethoxy-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one (I) and 8'-chloro-5'-(2-hydroxyethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one were selected for studies in rat models.

IT 460346-61-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl]glycine and study of its activity as phosphodiesterase (PDE7) inhibitor)

10/ 667,111

RN 460346-61-6 CAPLUS

CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT **460346-02-5P**, 8'-Chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-28-5P**, 8'-Chloro-5'-(2-hydroxyethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-31-0P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one derivs. and study of their activity as phosphodiesterase (PDE-7) inhibitors)


RN 460346-02-5 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-hydroxyethoxy)- (9CI) (CA INDEX NAME)



RN 460346-28-5 CAPLUS


CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-(2-hydroxyethoxy)- (9CI) (CA INDEX NAME)



10/ 667,111

RN 460346-31-0 CAPLUS


CN Acetonitrile, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)



IT 460346-14-9P, 8'-Chloro-5'-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-23-0P, 5'-Carboxymethoxy-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-32-1P, 8'-Chloro-5'-(1H-tetrazol-5-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one 460346-33-2P, 8'-Chloro-5'-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one derivs. and study of their activity as phosphodiesterase (PDE-7) inhibitors)


RN 460346-14-9 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 460346-23-0 CAPLUS

CN Acetic acid, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-32-1 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[(1H-tetrazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 460346-33-2 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methoxy]- (9CI) (CA INDEX NAME)



IT **460346-15-0P**, 8'-Chloro-5'-[2-(dimethylamino)ethoxy]spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(1'H)-one **460346-16-1P**, 8'-Chloro-5'-[(2-aminoethoxy)spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(1'H)-one **460346-18-3P**, 8'-Chloro-5'-[2-(methylamino)ethoxy]spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(1'H)-one **460346-19-4P**,


8'-Chloro-5'-[2-(2-aminoethoxy)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-21-8P**, 8'-Chloro-5'-[3-(dimethylamino)propoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-26-3P**, 8'-Chloro-5'-(3-sulfopropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-29-6P**, 8'-Chloro-5'-(5-ethoxycarbonylfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-30-9P**, 8'-Chloro-5'-(5-carboxyfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-57-0P**, 8'-Chloro-5'-[3-(dimethylamino)-2-hydroxypropoxy]spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one **460346-59-2P**, 8'-Chloro-5'-(3-methylamino-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of chlorospiro[cyclohexane-1,4'-quinazolin]-2'(1'H)-one derivs. and study of their activity as phosphodiesterase (PDE7) inhibitors)


RN 460346-15-0 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(dimethylamino)ethoxy]- (9CI) (CA INDEX NAME)



RN 460346-16-1 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 5'-(2-aminoethoxy)-8'-chloro- (9CI) (CA INDEX NAME)



RN 460346-18-3 CAPLUS


CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(methylamino)ethoxy]- (9CI) (CA INDEX NAME)

10/ 667,111




RN 460346-19-4 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 5'-[2-(2-aminoethoxy)ethoxy]-8'-chloro- (9CI) (CA INDEX NAME)




RN 460346-21-8 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[3-(dimethylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 460346-26-3 CAPLUS


CN 1-Propanesulfonic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)



10/ 667,111


RN 460346-29-6 CAPLUS

CN 2-Furancarboxylic acid, 5-[[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4' (1'H)-quinazolin]-5'-yl)oxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460346-30-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4' (1'H)-quinazolin]-5'-yl)oxy)methyl]- (9CI) (CA INDEX NAME)




RN 460346-57-0 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[3-(dimethylamino)-2-hydroxypropoxy]- (9CI) (CA INDEX NAME)



RN 460346-59-2 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-5'-[2-hydroxy-3-(methylamino)propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:689238 CAPLUS

DOCUMENT NUMBER: 141:253666

TITLE: Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1

AUTHOR(S): Lorthiois, Edwige; Bernardelli, Patrick; Vergne, Fabrice; Oliveira, Chrystelle; Mafroud, Abdel-Kader; Proust, Emmanuelle; Heuze, Lamia; Moreau, Francois; Idrissi, Moulay; Tertre, Anita; Bertin, Bernadette; Coupe, Magali; Wrigglesworth, Roger; Descours, Arnaud; Soulard, Patricia; Berna, Patrick

CORPORATE SOURCE: Pfizer Global Research and Development, Fresnes, 94265, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(18), 4623-4626

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis and SAR studies of spiroquinazolinones as novel PDE7 inhibitors are discussed. The best compds. from the series displayed nanomolar inhibitory affinity and were selective vs. other PDE isoenzymes.

IT 460345-65-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(spiroquinazolinones as PDE7 inhibitors)

RN 460345-65-7 CAPLUS

10/ 667,111


CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-6'-methoxy-
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:246965 CAPLUS
DOCUMENT NUMBER: 140:270874
TITLE: Preparation of spirocondensed quinazolinones as
phosphodiesterase inhibitors
INVENTOR(S): Bernardelli, Patrick; Vergne, Fabrice; Mendes,
Chrystelle; Ducrot, Pierre
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1400244	A1	20040324	EP 2002-292275	20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
WO 2004026818	A1	20040401	WO 2003-IB3965	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004106631	A1	20040603	US 2003-667111	20030917
PRIORITY APPLN. INFO.:			EP 2002-292275	A 20020917
			US 2002-429507P	P 20021126
OTHER SOURCE(S):		MARPAT 140:270874		
GI				




AB Title compds. I [$m = 1, 2, 3$; $R_1 = \text{Me, Cl, Br, F}$; $R_2 = (\text{un})\text{substituted alkyl, heterocyclic}$] were prepd. for use as inhibitors of PDE-7 (no data). Thus, I [$R_1 = \text{Cl}$, $R_2 = \text{OCH}_2\text{CH}_2\text{NHCH}_2\text{CO}_2\text{Me}$] was treated with aqueous NH_3 to give I [$R_1 = \text{Cl}$, $R_2 = \text{OCH}_2\text{CH}_2\text{NHCH}_2\text{CONH}_2$].

IT **674336-44-8 674336-59-5**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors)


RN 674336-44-8 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-(2-hydroxyethoxy)- (9CI) (CA INDEX NAME)



RN 674336-59-5 CAPLUS

CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




IT **674336-41-5P 674336-46-0P 674336-51-7P**

674336-55-1P 674336-56-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors)


RN 674336-41-5 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[(methylthio)methoxy]- (9CI) (CA INDEX NAME)




RN 674336-46-0 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-(2-iodoethoxy)- (9CI) (CA INDEX NAME)




RN 674336-51-7 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-fluoro-5'-methoxy- (9CI) (CA INDEX NAME)




RN 674336-55-1 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-fluoro-5'-[3-(methylthio)propoxy]- (9CI) (CA INDEX NAME)



RN 674336-56-2 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-fluoro-5'-[(methylthio)methoxy]- (9CI) (CA INDEX NAME)



IT 674336-60-8P 674336-61-9P 674336-62-0P


674336-63-1P 674336-64-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of spirocondensed quinazolinones as phosphodiesterase inhibitors)


RN 674336-60-8 CAPLUS

CN Acetamide, 2-[[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 674336-61-9 CAPLUS

CN Spiro[cyclopentane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[(methylsulfinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 674336-62-0 CAPLUS

CN Acetamide, N-[2-[[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclopentane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 674336-63-1 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-fluoro-5'-[3-(methylsulfinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 674336-64-2 CAPLUS

CN Spiro[cyclopentane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-fluoro-5'-[(methylsulfinyl)methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:754361 CAPLUS

DOCUMENT NUMBER: 137:247713

TITLE: Preparation of spirotricyclic quinoline derivatives and analogs and their use as phosphodiesterase-7 inhibitors

INVENTOR(S): Bernardelli, Patrick; Ducrot, Pierre; Lorthiois, Edwige; Vergne, Fabrice

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 116 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076953	A1	20021003	WO 2001-EP3355	20010321
W: US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2441313	AA	20020926	CA 2002-2441313	20020318
WO 2002074754	A1	20020926	WO 2002-EP3594	20020318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1373224	A1	20040102	EP 2002-732544	20020318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300459	A	20040216	EE 2003-459	20020318
BR 2002008192	A	20040302	BR 2002-8192	20020318
JP 2004529123	T2	20040924	JP 2002-573763	20020318
US 2002198198	A1	20021226	US 2002-101996	20020319
BG 108181	A	20040930	BG 2003-108181	20030917
NO 2003004187	A	20031015	NO 2003-4187	20030919
US 2004214843	A1	20041028	US 2004-852404	20040524
PRIORITY APPLN. INFO.:			WO 2001-EP3355	A 20010321
			WO 2002-EP3594	W 20020318
			US 2002-101996	B1 20020319

OTHER SOURCE(S): MARPAT 137:247713
GI

AB Title compds. I [X1-4 = N provided that not more than two of X1-4 simultaneously represent N; C-R1; R1 = Q1, alk(en/yn)yl, Q1 = H, halo, CN, NO2, SO3H, etc.; when X1-2 both represent C-R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring; X is O, NR9; R9 = H, CN, OH, NH2, alk(en/yn)yl; Y = O, S, NR12; R12 = H, CN, OH, NH2, alk(en/yn)yl; Z = CH-NO2, O, S, NR13; R13 = H, CN, OH, NH2, aryl, heteroaryl, cycloalkyl, etc.; A = cyclohexyl, heterocyclyl, etc. and tautomeric analogs] were prepared For instance, II was prepared from 2,5-dichlorophenylurea, cyclohexanone and polyphosphoric acid in 7% yield. II had IC50 = 0.014 μ M for the PDE7 receptor. I are useful for the treatment of autoimmune

diseases, osteoarthritis, etc.


IT **460345-65-7P**, 8'-Chloro-6'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE7 inhibitor; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)

RN 460345-65-7 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-6'-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:736240 CAPLUS

DOCUMENT NUMBER: 137:247712

TITLE: Preparation of spirotricyclic quinoline derivatives and analogs and their use as phosphodiesterase-7 inhibitors

INVENTOR(S): Bernardelli, Patrick; Ducrot, Pierre; Lorthiois, Edwige; Vergne, Fabrice

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 187 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074754	A1	20020926	WO 2002-EP3594	20020318
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002076953	A1	20021003	WO 2001-EP3355	20010321
W:	US			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
CA 2441313	AA	20020926	CA 2002-2441313	20020318

EP 1373224	A1	20040102	EP 2002-732544	20020318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300459	A	20040216	EE 2003-459	20020318
BR 2002008192	A	20040302	BR 2002-8192	20020318
JP 2004529123	T2	20040924	JP 2002-573763	20020318
BG 108181	A	20040930	BG 2003-108181	20030917
NO 2003004187	A	20031015	NO 2003-4187	20030919
PRIORITY APPLN. INFO.:			WO 2001-EP3355	W 20010321
			WO 2002-EP3594	W 20020318
OTHER SOURCE(S):		MARPAT 137:247712		
GI				




AB Title compds. I [X1-4 = N provided that not more than two of X1-4 simultaneously represent N; C-R1; R1 = Q1, alk(en/yn)yl, Q1 = H, halo, CN, NO2, SO3H, etc.; when X1-2 both represent C-R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring; X is O, NR9; R9 = H, CN, OH, NH2, alk(en/yn)yl; Y = O, S, NR12; R12 = H, CN, OH, NH2, alk(en/yn)yl; Z = CH-NO2, O, S, NR13; R13 = H, CN, OH, NH2, aryl, heteroaryl, cycloalkyl, etc.; A = cyclohexyl, heterocyclyl, etc. and tautomeric analogs] were prepared For instance, II was prepared from 2,5-dichlorophenylurea, cyclohexanone and polyphosphoric acid in 7% yield. II had IC50 = 0.014 μ M for the PDE7 receptor. I are useful for the treatment of autoimmune diseases, osteoarthritis, etc.

IT **460346-12-7P**, 8'-Chloro-6'-iodo-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-28-5P**, 8'-Chloro-5'-(2-hydroxyethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-31-0P**, 8'-Chloro-5'-cyanomethoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-37-6P**, 6'-(4-Carboxyphenyl)-8'-chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-60-5P**, 8'-Chloro-5'-[2-((ethoxycarbonyl)methyl)amino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE7 inhibitor; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)


RN 460346-12-7 CAPLUS

CN Spiro[cyclohexane-1,4' (1'H)-quinazolin]-2' (3'H)-one, 8'-chloro-6'-iodo-5'-methoxy- (9CI) (CA INDEX NAME)




RN 460346-28-5 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-(2-hydroxyethoxy)- (9CI) (CA INDEX NAME)




RN 460346-31-0 CAPLUS

CN Acetonitrile, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-37-6 CAPLUS

CN Benzoic acid, 4-(8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-6'-yl)- (9CI) (CA INDEX NAME)



RN 460346-60-5 CAPLUS

CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT **460345-65-7P**, 8'-Chloro-6'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-02-5P**, 8'-Chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-13-8P**, 8'-Chloro-6'-cyano-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-14-9P**, 8'-Chloro-5'-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-15-0P**, 8'-Chloro-5'-(2-dimethylaminoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-16-1P**, 8'-Chloro-5'-(2-aminoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-18-3P**, 8'-Chloro-5'-[2-(methylamino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-19-4P**, 8'-Chloro-5'-[2-(2-aminoethoxy)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-21-8P**, 8'-Chloro-5'-(3-(dimethylamino)propoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-22-9P**, 8'-Chloro-5'-ethoxycarbonylmethoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-23-0P**, 5'-Carboxymethoxy-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-24-1P**, 5'-(3-(Carboxy)propoxy)-8'-chlorospiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-26-3P**, 8'-Chloro-5'-(3-sulfopropoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-27-4P** **460346-29-6P**, 8'-Chloro-5'-(5-ethoxycarbonylfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-30-9P**, 8'-Chloro-5'-(5-carboxyfuran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-32-1P**, 8'-Chloro-5'-(1H-tetrazol-5-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-33-2P**, 8'-Chloro-5'-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-36-5P**, 8'-Chloro-6'-iodo-5'-(2-(dimethylamino)ethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-38-7P**, 6'-(3-Carboxyphenyl)-8'-chloro-5'-methoxyspiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-48-9P**, 8'-Chloro-5'-methoxy-6'-[4-[[4-methylpiperazine]carbonyl]phenyl]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-57-0P**, 8'-Chloro-5'-(3-dimethylamino-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-59-2P**, 8'-Chloro-5'-(3-methylamino-2-hydroxypropoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-61-6P**, 8'-Chloro-5'-[2-(((carboxy)methyl)amino)ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one hydrochloride **460346-63-8P**, 8'-Chloro-5'-(2-((methanesulfonyl)amino)-2-oxoethoxy)spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one **460346-64-9P**, 8'-Chloro-5'-[2-[(5-methylisoxazol-3-ylmethyl)amino]ethoxy]spiro[cyclohexane-1,4'-quinazolin]-2' (1'H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(PDE7 inhibitor; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)


RN 460345-65-7 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-6'-methoxy- (9CI) (CA INDEX NAME)




RN 460346-02-5 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-methoxy- (9CI) (CA INDEX NAME)




RN 460346-13-8 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazoline]-6'-carbonitrile, 8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxo- (9CI) (CA INDEX NAME)




RN 460346-14-9 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 460346-15-0 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[2-(dimethylamino)ethoxy]- (9CI) (CA INDEX NAME)




RN 460346-16-1 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 5'-(2-aminoethoxy)-8'-chloro- (9CI) (CA INDEX NAME).




RN 460346-18-3 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[2-(methylamino)ethoxy]- (9CI) (CA INDEX NAME)




RN 460346-19-4 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 5'-[2-(2-aminoethoxy)ethoxy]-8'-chloro- (9CI) (CA INDEX NAME)




RN 460346-21-8 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[3-(dimethylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 460346-22-9 CAPLUS


CN Acetic acid, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



10/ 667,111


RN 460346-23-0 CAPLUS

CN Acetic acid, [(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-24-1 CAPLUS

CN Butanoic acid, 4-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-26-3 CAPLUS

CN 1-Propanesulfonic acid, 3-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]- (9CI) (CA INDEX NAME)




RN 460346-27-4 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]- (9CI) (CA INDEX NAME)




RN 460346-29-6 CAPLUS

CN 2-Furancarboxylic acid, 5-[[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4' (1'H)-quinazolin]-5'-yl)oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460346-30-9 CAPLUS

CN 2-Furancarboxylic acid, 5-[[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4' (1'H)-quinazolin]-5'-yl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 460346-32-1 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[(1H-tetrazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 460346-33-2 CAPLUS


CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methoxy]- (9CI) (CA INDEX NAME)



10/ 667,111


RN 460346-36-5 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-(dimethylamino)ethoxy]-6'-iodo- (9CI) (CA INDEX NAME)




RN 460346-38-7 CAPLUS

CN Benzoic acid, 3-(8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-6'-yl)- (9CI) (CA INDEX NAME)




RN 460346-48-9 CAPLUS

CN Piperazine, 1-[4-(8'-chloro-2',3'-dihydro-5'-methoxy-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-6'-yl)benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 460346-57-0 CAPLUS

CN Spiro[cyclohexane-1,4'(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[3-(dimethylamino)-2-hydroxypropoxy]- (9CI) (CA INDEX NAME)




RN 460346-59-2 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'(3'H)-one, 8'-chloro-5'-[2-hydroxy-3-(methylamino)propoxy]- (9CI) (CA INDEX NAME)



RN 460346-61-6 CAPLUS


CN Glycine, N-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 460346-63-8 CAPLUS

CN Acetamide, 2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 460346-64-9 CAPLUS


CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[2-[[5-methyl-3-isoxazolyl)methyl]amino]ethoxy]- (9CI) (CA INDEX NAME)



IT **460346-17-2P**, 8'-Chloro-5'-(2-(methanesulfonyl)ethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'-(1'H)-one **460346-20-7P**
460346-25-2P 460346-34-3P, 8'-Chloro-5'-(N-hydroxycarbamimidoylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'-(1'H)-one
460346-58-1P, 8'-Chloro-5'-(oxiran-2-ylmethoxy)spiro[cyclohexane-1,4'-quinazolin]-2'-(1'H)-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)


RN 460346-17-2 CAPLUS

CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-[2-(methylsulfonyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 460346-20-7 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]ethoxy]ethyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

Cl


RN 460346-25-2 CAPLUS
 CN Butanoic acid, 4-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'(1'H)-quinazolin]-5'-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 460346-34-3 CAPLUS
 CN Ethanimidamide, 2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 460346-58-1 CAPLUS
 CN Spiro[cyclohexane-1,4'-(1'H)-quinazolin]-2'-(3'H)-one, 8'-chloro-5'-(oxiranylmethoxy)- (9CI) (CA INDEX NAME)



IT 460346-35-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of spirotricyclic quinoline derivs. and analogs and use as phosphodiesterase-7 inhibitors)
 RN 460346-35-4 CAPLUS
 CN Ethanimidamide, 2-[(8'-chloro-2',3'-dihydro-2'-oxospiro[cyclohexane-1,4'-(1'H)-quinazolin]-5'-yl)oxy]-N-[(ethoxycarbonyl)oxy]- (9CI) (CA INDEX NAME)

10/ 667,111



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:35:47 ON 08 FEB 2005)

FILE 'REGISTRY' ENTERED AT 15:36:18 ON 08 FEB 2005

L1 STRUCTURE UPLOADED
L2 0 S L1 SAMPLE
L3 50 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:37:41 ON 08 FEB 2005

L4 5 S L3

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
25.60	187.57

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-3.65	-3.65

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:38:37 ON 08 FEB 2005